Dr. Michael Andreeff, MD

Dr. Andreeff practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Andreeff's NPI, 1437263506, was assigned on August 18, 2006. Dr. Andreeff graduated from University of Heidelberg Faculty of Medicine in 1968. Dr. Andreeff holds Texas license H9035.

Dr. Andreeff's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Andreeff's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Andreeff practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Andreeff's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Andreeff's licenses on file in 2 states: Texas and Florida.

Dmand AI lists immune deficiency disease among the conditions Dr. Andreeff treats.

CMS data shows 41 Medicare services from Dr. Andreeff across 1 procedure code in 2024, all of them office visits, for 20 Medicare patients. Medicare paid $2,943 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 20 Medicare patients who saw Dr. Andreeff in 2024. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 2.78, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Andreeff's median patient age at 62, with 0% women.

In 2024, Dr. Andreeff wrote 37 Medicare Part D claims. CMS names the drug for 23 of them, across 1 drug with 11 or more claims each, at $121,332 in total drug cost. In 2023, CMS named 27 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Andreeff for performance year 2024, reported as part of a group. Dr. Andreeff accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Andreeff as offering telehealth.

Dmand AI links 644 papers to Dr. Andreeff, published from 2002 to 2025. 2017 was the busiest year, with 24. The most frequent topics are Leukemia, Myeloid, Acute, Apoptosis and Cell Line, Tumor. Dr. Andreeff has published most often in Blood. Dr. Andreeff's most frequent co-authors are Marina Y. Konopleva, MD, PhD, Hagop M. Kantarjian, MD and Steven M. Kornblau, MD.

Dmand AI links Dr. Andreeff to 3 clinical trials. Conditions studied include Hematologic Neoplasms, Hypereosinophilic Syndrome and Leukemia, Myeloid, Acute. M.D. Anderson Cancer Center sponsors the most, 3.

CMS Open Payments shows 76 general payments to Dr. Andreeff from 15 drug and device companies from 2016 to 2024. Consulting fees make up the largest share, 65% of the total. Daiichi Sankyo Inc. paid the most, $33,273. It also lists 3 research payments totaling $13,956 from 2020 to 2023.

Dr. Andreeff graduated from University of Heidelberg Faculty of Medicine in 1968.

Dr. Andreeff is in network with 15 carriers, including Aetna, Excellus BlueCross BlueShield and United Healthcare. HMO plans come from the most carriers, 10. Check the plan with the practice before a visit.